Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: A spokesman for California State University, Los Angeles, said Saturday that 106 staff members and 550 students have been told to stay at home and avoid contact with others. Thirty students and employees from the University of California, Los Angeles, remain quarantined. Those under quarantine were possibly exposed to a person with measles on each campus earlier this month. Many people have been cleared after proving their immunity with medical records or tests. The quarantines mark one of the most sweeping efforts by health officials to contain the nation’s measles outbreak, where cases have reached a 25-year high .
[A]: Nearly 700 from LA universities still in measles quarantine.


[Q]: The chamber’s top Republican, who said he was making enactment of the bill “one of my highest priorities,” issued his proposal at a time when the use of e-cigarettes is growing and underage vaping has soared, raising concerns by health expert s. The measure would apply to all tobacco products, e-cigarettes and vapor products and was co-sponsored by Sen. Tim Kaine, D-Va., whose state has also been a major tobacco producer. “Kentucky farmers don’t want their children to get hooked on tobacco products while they’re in middle school or high school any more than any parents anywhere want that to happen,” McConnell said on the Senate floor. Fourteen states, including Arkansas, California and Virginia, have enacted laws raising the minimum age for tobacco sales to 21, according to the anti-smoking Campaign for Tobacco-Free Kids. So have 470 municipalities, including New York City, Chicago, Boston and Minneapolis. Even so, the use of e-cigarettes and vaping has surged, with much of the increase among teenagers. The CDC says most e-cigarettes contain highly addictive nicotine, which can harm the development of young people’s brains and may them likelier to smoke cigarettes later in life. “Youth vaping is a public health crisis,” McConnell said. “It’s our responsibility as parents and public servants to do everything we can to keep these harmful products out of high schools and out of youth culture.” A government survey found that last year 1 in 5 U.S. high school students reported vaping the previous month. “Today, we are coming together to side with young people’s health,” said Kaine, acknowledging the rarity for bipartisan legislation at a time when the two parties can seldom find middle ground. The bill quickly won the endorsement of the American Cancer Society. Its advocacy organization, the Cancer Action Network, said the measure was a “welcome indication that Congress is taking the alarming crisis of increased youth tobacco use seriously and is committed to taking action.” The group also warned the sponsors to resist amendments that could let the federal government pre-empt stronger measures by states and municipalities, exempt some young people or exclude certain products. A similar bill was introduced last month by Sens. Brian Schatz, D-Hawaii, Todd Young, R-Ind., Dick Durbin, D-Ill., and Mitt Romney, R-Utah. Most experts agree e-cigarettes are less harmful than the paper-and-tobacco variety because they don’t produce all the cancer-causing byproducts found in smoke. But researchers say they are only beginning to understand the risks of e-cigarettes, which they think may damage the lungs and contribute to precancerous growths. McConnell has long been involved in tobacco issues. He helped pass the 2004 tobacco buyout, when the government provided billions of dollars for growers who lost money with the end of federal price supports. Kentucky has the highest cancer mortality rate in the country, with nearly 186 deaths per 100,000 residents in 2017, according to the federal Centers for Disease Control and Prevention. As health concerns about tobacco have grown in the U.S., demand and production of the crop have fallen in Kentucky, where it had long been a pillar of the state’s economy. Growers have been relying increasingly on industrial hemp, which McConnell has helped legalize. The CDC calls tobacco products the country’s top cause of preventable disease and death, with almost 40 million adult cigarette smokers. The agency says around 4.7 million middle school and high school students use at least one tobacco product, including e-cigarettes. Treating adults with smoking-related diseases costs the country nearly $170 billion annually for medical care. The country’s biggest tobacco company, Altria Group, has invested in the e-cigarette company Juul and has backed bills raising the minimum age for buying tobacco and vaping products to 21. Critics have suggested that support is aimed at forestalling tougher restrictions such as banning flavored vaping products and menthol cigarettes. ___ AP Health Writer Matthew Perrone contributed to this report.
[A]: Senate GOP leader would raise age for buying tobacco to 21.


[Q]: The Food and Drug Administration approved Medtronic’s CoreValve system based on U.S. clinical trials in which it was shown to be safe and effective while demonstrating low rates of stroke and valve leakage, the company said. Medtronic and Wall Street analysts had not expected the approval decision until April, giving the company a head start on efforts to seize market share from a similar rival product sold by Edwards Lifesciences Corp. News of the early CoreValve approval sent Edwards shares down nearly 5 percent. More than 100,000 people in the U.S. have severe aortic stenosis with about one-third too ill or frail for open-heart valve replacement surgery, making them candidates for CoreValve or the rival Edwards Sapien system. The systems, in which the replacement valve is threaded into place through an artery using a catheter - known as transcatheter aortic valve replacement, or TAVR - spares patient’s chest-cracking surgery, cutting down on recovery time. CoreValve has been available since 2007 in Europe, where it is not uncommon for medical devices to win approval several years ahead of the United States. “We estimate the U.S. TAVR market will be approximately $450 million in 2014,” said Glenn Novarro, an analyst with RBC Capital Markets. “With approval earlier than expected, share loss for Edwards will likely occur sooner than expected,” added Novarro, who sees Medtronic grabbing 20 percent of the U.S. TAVR market this year, rising to more than 30 percent by 2016. But CoreValve’s U.S. sales prospects may hinge on further legal proceedings after a U.S. jury earlier this week found that the Medtronic system infringes a patent held by Edwards and awarded Edwards more than $390 million in damages. Medtronic vowed to appeal the decision and oppose any request for an injunction. Edwards, meanwhile, said the patent infringement ruling entitled it to seek increased damages of up to three times the value of the award. The FDA approved CoreValve without first requiring an expert advisory panel to review the device and make recommendations to the agency. “The low rates of stroke and valve leakage with the CoreValve System - two of the most concerning complications of valve replacement because they increase the risk of death and have a dramatic impact on quality of life - set a new standard for transcatheter valves,” Dr. Jeffrey Popma, director of Interventional Cardiology at the Beth Israel Deaconess Medical Center in Boston and one of the lead investigators of the pivotal clinical trial, said in a statement. The CoreValve uses a smaller catheter than the currently approved Sapien, giving it a potential but temporary competitive edge. Edwards is awaiting U.S. approval of a next generation Sapien with a similarly smaller catheter. Both companies are also testing their systems in less high risk patients in hopes of broadening the potential patient population and market for the devices. Medtronic shares were up 18 cents at $59.29 in afternoon trading, while Edwards shares were off $3.49, or 4.8 percent, at $69.18, both on the New York Stock Exchange.
[A]:
U.S. FDA approves Medtronic heart valve system early.